Nothing Special   »   [go: up one dir, main page]

AR121036A1 - Compuesto para el secuestro de anticuerpos no deseables en un paciente - Google Patents

Compuesto para el secuestro de anticuerpos no deseables en un paciente

Info

Publication number
AR121036A1
AR121036A1 ARP200100819A ARP200100819A AR121036A1 AR 121036 A1 AR121036 A1 AR 121036A1 AR P200100819 A ARP200100819 A AR P200100819A AR P200100819 A ARP200100819 A AR P200100819A AR 121036 A1 AR121036 A1 AR 121036A1
Authority
AR
Argentina
Prior art keywords
compound
peptide
sequestration
patient
antibodies
Prior art date
Application number
ARP200100819A
Other languages
English (en)
Original Assignee
Ablevia Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablevia Biotech Gmbh filed Critical Ablevia Biotech Gmbh
Publication of AR121036A1 publication Critical patent/AR121036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona un compuesto para el secuestro de anticuerpos no deseables (por ejemplo, relacionados con una enfermedad autoinmune) en un paciente. El compuesto comprende un andamio de biopolímero inerte y al menos un primer péptido n-mer de la fórmula general P(– S – P)₍ₙ₋₁₎ y un segundo péptido n-mer de la fórmula general P(– S – P)₍ₙ₋₁₎; en donde, independientemente de cada aparición, P es un péptido con una longitud de secuencia de 2 - 13 aminoácidos y S es un espaciador no peptídico, en donde, independientemente para cada uno de los péptidos n-mers, n es un número entero de al menos 1, en donde cada uno de los péptidos n-mers está unido al andamio de biopolímero. También se proporcionan composiciones farmacéuticas que comprenden el compuesto, así como un método para secuestrar uno o más anticuerpos presentes en un individuo y un método para inhibir una reacción inmune para un tratamiento con un agente activo.
ARP200100819A 2019-03-23 2020-03-25 Compuesto para el secuestro de anticuerpos no deseables en un paciente AR121036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19164784.1A EP3715374A1 (en) 2019-03-23 2019-03-23 Compound for the sequestration of undesirable antibodies in a patient

Publications (1)

Publication Number Publication Date
AR121036A1 true AR121036A1 (es) 2022-04-13

Family

ID=65991526

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100819A AR121036A1 (es) 2019-03-23 2020-03-25 Compuesto para el secuestro de anticuerpos no deseables en un paciente

Country Status (17)

Country Link
US (1) US12011484B2 (es)
EP (3) EP3715374A1 (es)
JP (1) JP2022528736A (es)
KR (1) KR20210142615A (es)
CN (1) CN113631581A (es)
AR (1) AR121036A1 (es)
AU (1) AU2020249341A1 (es)
BR (1) BR112021018171A2 (es)
CA (1) CA3130187A1 (es)
DK (1) DK3898702T3 (es)
EA (1) EA202192085A1 (es)
ES (1) ES2927642T3 (es)
IL (1) IL286589A (es)
MX (2) MX2021011635A (es)
SG (1) SG11202108756TA (es)
TW (1) TW202102520A (es)
WO (1) WO2020193486A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986536B2 (en) * 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
JP2023542390A (ja) * 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー ウイルスベクターの有効性を増強するための化合物
TW202228784A (zh) * 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5578496A (en) 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
EP1135167A2 (en) 1998-12-09 2001-09-26 La Jolla Pharmaceutical Methods and formulations for reducing circulating antibodies
US6498244B1 (en) * 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
ES2248357T3 (es) 2000-07-07 2006-03-16 Medmira Inc. Composicion de antigeno mosaico de vhc.
DK1328297T3 (da) 2000-10-16 2010-02-01 Cytoguide Aps Funktionen af en haptoglobin-hæmoglobin receptor og anvendelser heraf
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
EP1597271B1 (de) 2003-01-31 2013-03-06 Max-Delbrück-Centrum Für Molekulare Medizin Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung
US20040258683A1 (en) 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
WO2005023848A2 (en) 2003-09-09 2005-03-17 Gardner, Rebecca, Katherine Adenoviral epitopes
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DE102004034008A1 (de) * 2004-07-14 2006-02-09 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Corticoid-Konjugaten
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
EP1832600A1 (en) 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptides against autoantibodies associated with glaucoma and use of these peptides
CA2653600A1 (en) * 2006-05-31 2007-12-06 The Children's Hospital Of Philadelphia Compositions and methods for detection and modulation of t cell mediated immune responses against viral vectors utilized for gene therapy
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP2308514B1 (en) * 2007-03-23 2013-06-05 to-BBB Holding B.V. Conjugates for targeted drug delivery across the blood-brain barrier
WO2009027063A2 (en) 2007-08-24 2009-03-05 Julius-Maximilians-Universität Würzburg MUTANT DOUBLE CYCLIZED RECEPTOR PEPTIDES INHIBITING β1-ADRENOCEPTOR ANTIBODIES
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
US8210547B2 (en) 2009-06-16 2012-07-03 Toyota Motor Engineering & Manufacturing North America, Inc. Active magneto-rheological spring assemblies and vehicle suspension systems incorporating the same
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
EP2498803A4 (en) 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII IMMUNOGENICITY T LYMPHOCYTE T EPOXY VARIANTS
US20130079280A1 (en) 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP2402016A1 (en) 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
EP3763729B1 (en) 2010-11-25 2022-07-06 Imcyse SA Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
JP4857396B1 (ja) 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
ES2626881T3 (es) 2012-11-12 2017-07-26 Apitope International Nv Péptidos derivados del factor VIII para uso en el tratamiento de la hemofilia A
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP3059244B1 (en) 2013-10-15 2020-08-26 The University of Tokyo C-met protein agonist
HUE054034T2 (hu) 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
WO2015181393A1 (en) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Novel sfti and cyclotide based peptides
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
CN106170303B (zh) 2014-11-20 2019-10-25 法罗斯根有限公司 通过半胱天冬酶激活的前体药物
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
CN109996812A (zh) 2016-09-08 2019-07-09 加利福尼亚大学董事会 用于诊断和治疗重症肌无力的肽及其用途
WO2018102668A1 (en) 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
CZ2016826A3 (cs) 2016-12-22 2018-07-04 Contipro A.S. Léčivý prostředek s nosičem na bázi hyaluronanu a/nebo jeho derivátů, způsob výroby a použití
US20190374650A1 (en) 2017-02-22 2019-12-12 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer/biomacromolecule conjugates
SG11201908422YA (en) 2017-03-15 2019-10-30 Polyneuron Pharmaceuticals Ag Glycopolymers sequestering carbohydrate-binding proteins
BR112020000995A2 (pt) 2017-07-17 2020-09-08 Spark Therapeutics, Inc. métodos e usos de aférese

Also Published As

Publication number Publication date
EP3715374A1 (en) 2020-09-30
EP3960769A1 (en) 2022-03-02
SG11202108756TA (en) 2021-10-28
ES2927642T3 (es) 2022-11-08
DK3898702T3 (da) 2022-09-26
BR112021018171A2 (pt) 2021-11-16
US12011484B2 (en) 2024-06-18
TW202102520A (zh) 2021-01-16
IL286589A (en) 2021-12-01
AU2020249341A1 (en) 2021-11-18
EP3898702A1 (en) 2021-10-27
MX2024005883A (es) 2024-05-29
EA202192085A1 (ru) 2021-12-10
US20220062435A1 (en) 2022-03-03
EP3898702B1 (en) 2022-06-29
CN113631581A (zh) 2021-11-09
MX2021011635A (es) 2022-01-04
JP2022528736A (ja) 2022-06-15
CA3130187A1 (en) 2020-10-01
KR20210142615A (ko) 2021-11-25
WO2020193486A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
AR121036A1 (es) Compuesto para el secuestro de anticuerpos no deseables en un paciente
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
AR127620A2 (es) Métodos para la elaboración de polipéptidos procesados proteolíticamente
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
DOP2013000172A (es) Composicion farmaceutica
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
CL2019003324A1 (es) Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)
AR092857A1 (es) Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
PH12019500954A1 (en) Vaccine against porcine parvovirus
BR112013003101A2 (pt) inibidores do vírus da hepatite c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
MX2023003377A (es) Compuesto para aumentar la eficacia de los vectores virales.
AR042910A1 (es) Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
AR127142A1 (es) Arn circular y método de preparación del mismo
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2019005775A (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
BR112023021654A2 (pt) Vacina contra vírus
EA201890160A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
AR123581A1 (es) Compuesto para el secuestro de anticuerpos anti peg no deseables en un paciente
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
EA201890334A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с